Licensing agreement signed
Thericon has signed and exclusive licensing agreement with the Heidelberg University for the two patent families of the real-time multispectral imaging technology. The two patent… Read More »Licensing agreement signed
Thericon has signed and exclusive licensing agreement with the Heidelberg University for the two patent families of the real-time multispectral imaging technology. The two patent… Read More »Licensing agreement signed
We registered last minute to attend the Sachs European HealthTech CEO Forum in Zürich on Feb. 18. Nikolaos Deliolanis will pitch our venture at 12:50… Read More »See you at #Sachs_EHTF
At the Innovation for Health Global Investor Forum, Thericon was among three out of ten medtech companies selected to progress to the finals of the… Read More »Thericon reaches finals of the I4H2020 pitch competition
Thericon will attend the LSX World Congress taking place on Feb 4-5 in London. Nikolaos Deliolanis will pitch our venture to potential investors. We will… Read More »See you at the LSX World Congress!
We just received a notification that our patent application CN1065722792A will be granted. Fingers crossed for CN106999021A!
The proposal submitted by Thericon under the Horizon 2020’s SME Instrument program was scored as a high quality project proposal in a highly competitive evaluation… Read More »Thericon receives the Seal of Excellence
Our application for a patent for “Methods and means for multispectral imaging” has been granted by the USPTO and published as US10481095B2.
Meet Thericon at Medica 2019, November 18-21 in Düsseldorf Germany! We are exhibiting in two areas: Hall 10, Booth G05 inside Fraunhofer IPA and Hall… Read More »we are exhibiting at Medica
Multiparametric imaging has been tested in bladder cystoscopies of 10 patients with bladder, and showed zero-false positives compared to existing imaging methods. Read the paper… Read More »Pilot bladder cancer study published